HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200301 Nov 1, 2021 By sarahjibrin
Nov 1, 2021 By sarahjibrin HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200301
Sep 23, 2021 By sarahjibrin HiFiBiO Therapeutics Contributes to CoVIC-Led Science Publication on SARS-CoV-2 Spike Antibodies Effective Against Variants of Concern
Aug 9, 2021 By sarahjibrin HiFiBiO Strengthens its Senior Leadership Team in Preparation for First-in-Human Studies of Two Lead Immunoncology Programs and a Sustainable Pipeline
Jun 17, 2021 By sarahjibrin FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease
Jun 14, 2021 By sarahjibrin HiFiBiO Therapeutics Closes $75 Million Series D Financing to Accelerate Pipeline with Two Lead Immuno-Oncology Programs and Validate its DIS™ Approach in the Clinic
Jun 11, 2021 By sarahjibrin HiFiBiO Therapeutics Announces Publication in Science Advances of its High-Throughput Functional Screening for Next-Generation Cancer Immunotherapy
May 11, 2021 By sarahjibrin HiFiBiO Therapeutics Announces Publication in Nature Communications on its SARS-CoV-2 Neutralizing Monoclonal Antibody
Apr 12, 2021 By sarahjibrin Clinical approach and biomarker strategy for HFB301001, a novel OX40 agonistic antibody
Apr 12, 2021 By sarahjibrin HFB9-2, a novel Galectin 9 neutralizing antibody for the treatment of AML and other cancers
Apr 12, 2021 By sarahjibrin Mechanism of Action and Biomarker Strategy for HFB200301, an Anti-TNFR2 Agonist Antibody for the Treatment of Cancer
